2C-T-21

Discovery

2C-T-21 was first synthesized by Alexander Shulgin as part of his systematic exploration of thio-substituted phenethylamines — compounds built on a shared 2,5-dimethoxyphenethylamine scaffold with varying sulfur-containing groups at the 4-position. The compound appears as Entry #49 in PiHKAL: A Chemical Love Story (1991),^[1] where Shulgin reported self-experimentation results placing the active oral dose at 8–12 mg with effects lasting 7–10 hours.^[7] He described it as "about as potent a phenethylamine as they come."

Research and characterization

For over two decades after publication, 2C-T-21 remained pharmacologically uncharacterized beyond Shulgin's qualitative reports. Halberstadt et al. published the first receptor binding data in 2023, confirming potent 5-HT₂A affinity and measuring behavioral potency in animal models.^[6] Wagmann et al. separately demonstrated that 2C-T-21 directly inhibits both MAO-A and MAO-B enzymes — a finding with significant safety implications that had not been anticipated from Shulgin's original reports.^[5]

Market appearance and scheduling

2C-T-21 appeared on the research chemical market in the early 2000s alongside other Shulgin phenethylamines, though its user base remained small relative to 2C-T-2 or 2C-T-7. No specific incident prompted scheduling; control has followed class-wide phenethylamine actions in the United Kingdom (2002), Canada (2016), and Germany (2016). In the United States, 2C-T-21 is not specifically scheduled, though the Federal Analogue Act is likely applicable.

Structural class

2C-T-21 belongs to the 2C-T-x series — a subclass of 2C phenethylamines defined by a 2,5-dimethoxyphenethylamine scaffold with a sulfur-containing substituent at the 4-position. The "2C" designation indicates two carbons between the amine nitrogen and the aromatic ring; the "T" denotes the thio (sulfur) linkage.

What distinguishes 2C-T-21 from its siblings is a 2-fluoroethylthio group (−S−CH₂−CH₂F) at C4 — where 2C-T-2 carries a simple ethylthio group and 2C-T-7 a propylthio chain. The terminal fluorine atom increases the polarity of the thioether chain relative to the unfluorinated analogs, altering how the molecule interacts with metabolic enzymes and potentially explaining its distinct duration and potency profile.

Molecular identity

The molecule comprises a 2,5-dimethoxybenzene ring substituted at C1 with an ethylamine chain and at C4 with the 2-fluoroethylthio group. No chirality centers are present — 2C-T-21 is achiral.^[8]

Physical properties

Published physical property data for 2C-T-21 are sparse. Melting point, aqueous solubility, and stability profiles have not been reported in the accessible literature. The hydrochloride salt is commercially available as an analytical reference standard.^[8]

Mechanism of action

2C-T-21 produces psychedelic effects primarily through agonism at the serotonin 5-HT₂A receptor, the same target responsible for the perceptual effects of LSD, psilocybin, and mescaline.^[6] It also activates 5-HT₂C receptors and acts as a partial agonist at 5-HT₂B receptors.^[6] Unlike classical tryptamine psychedelics, 2C-T-21 does not significantly interact with monoamine transporters — it does not release serotonin, dopamine, or norepinephrine the way MDMA does.^[9]

A pharmacologically significant secondary action is direct inhibition of both MAO-A and MAO-B enzymes.^[5] This dual property — 5-HT₂A agonism layered over monoamine oxidase inhibition — is shared across the 2C-T class but not found in tryptamine or lysergamide psychedelics. The MAO inhibition may contribute to the stimulant-like quality reported by users, and it creates drug interaction risks that exceed those of non-MAO-inhibiting psychedelics.

In animal behavioral assays, 2C-T-21 produces dose-dependent psychedelic-like responses, though with approximately four-fold lower potency than 2C-T-2 — a difference attributed to the electron-withdrawing fluorine atom on the thioether chain.^[6]

The 2C-T series as a class also binds TAAR1 (TAAR1), though the contribution of this target to the subjective experience is not understood.^[9]

Pharmacokinetics

No controlled human pharmacokinetic studies have been published for 2C-T-21. Oral bioavailability, peak plasma concentration timing, half-life, and clearance parameters are unknown.

Metabolic pathway data come from structurally related compounds. For 2C-T-2 and 2C-T-7, MAO-A and MAO-B are the primary enzymes responsible for breaking down the molecule, with the liver enzyme CYP2D6 contributing to a lesser extent.^[10] These pathways are expected to apply to 2C-T-21 by structural analogy, though the terminal fluorine may alter how quickly the compound is metabolized — a hypothesis not yet tested experimentally.inferred

Because 2C-T-21 depends on MAO enzymes for its own clearance, anything that inhibits those enzymes — including other drugs or the compound's own MAO-inhibiting activity — would slow elimination and raise blood levels.^[10]

Where it acts

As a potent serotonin 2A receptor agonist,^[6] 2C-T-21 is expected to activate layer V cortical pyramidal neurons in prefrontal and association cortices — the same neural populations targeted by psilocybin and LSD. In neuroimaging studies of those compounds, this activation disrupts default mode network integrity, loosens thalamocortical gating, and increases global brain connectivity, producing the characteristic psychedelic shift in perception and cognition.

The additional monoamine oxidase inhibition^[5] introduces a secondary layer: by slowing the breakdown of serotonin, dopamine, and norepinephrine, the compound may locally elevate monoamine levels in ways that account for the stimulant-like energy and social warmth described in user reports.^[2] This pharmacological layering — receptor agonism atop enzyme inhibition — distinguishes the 2C-T class from tryptamine and lysergamide psychedelics.

Theoretical frameworks

The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that 5-HT₂A agonism loosens the brain's high-level predictions, allowing raw sensory information to flow more freely. The gentle visual effects and prominent socioemotional character of 2C-T-21 may reflect a dose range that modestly relaxes these predictions without fully destabilizing perception.

Whether 2C-T-21 promotes structural brain changes — the psychoplastogen hypothesis — has not been tested. Its potent 5-HT₂A binding makes it a plausible candidate, but this remains speculative until direct plasticity studies are conducted.

Toxicity

No lethal dose, therapeutic index, or controlled toxicology data exist for 2C-T-21. All toxicity assessments are class-level inferences, not substance-specific findings.inferred

Within the broader 2C series, at least five deaths have been documented, with excited delirium, rapid heart rate, elevated blood pressure, and dangerous overheating as characteristic features of severe intoxication.^[4] One death from mono-intoxication with the structurally similar 2C-T-7 — the closest published precedent for 2C-T-21 — has been reported.^[3]

Blood pressure and heart rate elevation are expected based on the pharmacology of related 2C compounds.^[12][13]

Psychological risks

No controlled data on psychological adverse events specific to 2C-T-21 exist. Community reports (25 on Erowid) document approximately 16–20% adverse psychological experience rate — 4 difficult experiences and 1 bad trip^[2] — comparable to other serotonergic psychedelics in uncontrolled settings.

Standard psychedelic psychological risks apply: acute anxiety, panic, paranoia, psychotic episodes (particularly in individuals with personal or family history of psychotic disorders), and depersonalization that may persist beyond the acute phase. The narrow active dose range (8–12 mg)^[7] means dosing errors of 2–3 mg above the intended dose can substantially escalate intensity and psychological distress.

Tolerance & dependence

Tolerance develops rapidly after a single dose, consistent with 5-HT₂A downregulation seen across all serotonergic psychedelics. Full baseline sensitivity returns within approximately 7 days. Cross-tolerance extends to other 5-HT₂A agonists including LSD, psilocybin, mescaline, and other 2C compounds.citation needed

No evidence of physical dependence, withdrawal, or compulsive redosing has been reported. Dependence liability is consistent with the low abuse potential documented for serotonergic psychedelics as a class.

Drug interactions

The combination of 5-HT₂A agonism and direct monoamine oxidase inhibition gives 2C-T-21 an interaction risk profile exceeding that of non-MAO-inhibiting psychedelics.

Monoamine oxidase inhibitors — pharmaceutical (phenelzine, tranylcypromine, moclobemide) and botanical (harmaline, Banisteriopsis caapi, Syrian rue) — represent the most dangerous interaction. MAO enzymes are the primary metabolic pathway for the 2C-T class,^[10] so co-administration impairs clearance while 2C-T-21's own MAO-inhibiting activity^[5] adds further enzyme blockade. The result is a compounding interaction with risk of serotonin syndrome and dangerous blood pressure spikes.safety citation needed

Serotonergic medications (SSRIs, SNRIs, tricyclic antidepressants, triptans, tramadol) increase serotonin syndrome risk through additive serotonergic load. Chronic SSRI use may also reduce psychedelic effects through 5-HT₂A receptor downregulation.^[15]

Lithium produces synergistic serotonergic activity and lowers the seizure threshold — a combination associated with severe adverse events across serotonergic psychedelics.safety citation needed

Stimulants (amphetamines, cocaine) compound cardiovascular stress — elevated blood pressure, rapid heart rate, and abnormal heart rhythms.

Cannabis may intensify the psychedelic experience in a dose-dependent manner,^[16] increasing the probability of overwhelming or difficult experiences.

Tramadol carries dual risk: serotonergic synergy and seizure threshold reduction.safety citation needed

Contraindications

The following contraindications are inferred from the pharmacological profile and class-level evidence. No substance-specific contraindication studies exist.inferred

Concurrent MAOI therapy is an absolute contraindication. 2C-T-21 depends on MAO enzymes for clearance^[10] while simultaneously inhibiting those same enzymes^[5] — a pharmacokinetic-pharmacodynamic trap in which the drug cannot be cleared while amplifying monoaminergic activity.

Personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar I with psychotic features) is an absolute contraindication, consistent with all serotonergic psychedelics.

Heart conditions (uncontrolled high blood pressure, coronary artery disease, irregular heart rhythms) represent a relative contraindication given the expected cardiovascular effects and confirmed 5-HT₂B partial agonism.

Liver impairment is a relative contraindication — impaired liver function may substantially alter drug exposure because first-pass metabolism involves MAO and CYP enzymes.safety citation needed

Concurrent serotonergic medication (SSRIs, SNRIs, TCAs, triptans, lithium) is a relative to absolute contraindication depending on the agent and dose, due to serotonin syndrome risk.

Pregnancy and lactation are absolute contraindications in the absence of reproductive toxicology data.safety citation needed

Seizure disorders represent a relative contraindication, particularly in combination with other seizure-threshold-lowering substances.

2C-T-21 is not controlled under any United Nations scheduling convention (1961, 1971, or 1988 treaties). National-level control has followed class-wide phenethylamine scheduling actions rather than substance-specific regulatory proceedings. No formal risk assessment by the EMCDDA or any equivalent body has been published. In jurisdictions without explicit scheduling, structural analog or generic legislation may apply based on structural similarity to controlled 2C-T compounds.